Allergic Reactions

Graphic of two hands shaking under a red and purple light

Pharma

ARS inks ex-US licensing pact for Neffy worth up to $465M

ARS will receive up to $465 million in a new licensing pact with ALK-Abelló to sell its epinephrine nasal spray Neffy in certain ex-U.S. territories.

Fraiser Kansteiner Nov 11, 2024 9:44am

peanuts

ARS has 'blue sky opportunity' in launching neffy, analyst says

Aug 21, 2024 12:48pm